Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 2Recruiting 2Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Gastrointestinal 1Endocrine 1CNS 1

Conditions

Neuroendocrine Tumors 11Gastro-enteropancreatic neuroendocrine tumor 2Pheochromocytoma 1Paraganglioma 1Meningioma 1Glioblastoma 1Extensive Stage Small Cell Lung Cancer 1Carcinoma, Neuroendocrine 1Carcinoma, Merkel Cell 1Carcinoma 1Carcinoid Tumor 1Advanced Neuroendocrine Neoplasm 1Adenoma, Islet Cell 1

Interventions

Specimen Handling 3Temozolomide 2Magnetic Resonance Spectroscopy 2tipifarnib 1talazoparib 1pembrolizumab 1olaparib 1lutetium Lu 177 dotatate 1lanreotide 1copper dotatate CU-64 1Staining and Labeling 1Nivolumab 1Lutetium-177 1Lutetium 1Ipilimumab 1Contrast Media 1CTLA-4 Antigen 1Biopsy 1Axitinib 16-fluorodopamine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Pheochromocytoma × lutetium Lu 177 dotatate × Clear all
NCT04711135 2026-02-12

NETTER-P

Advanced Accelerator Applications

Phase 2 Active not recruiting
11 enrolled 14 charts 1 FDA
CNSEndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Paraganglioma, Pheochromocytoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡